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ARTICLE
TRPM7 Channel Is Regulated by Magnesium Nucleotides 
via its Kinase Domain
Philippe Demeuse, Reinhold Penner, and Andrea Fleig
Laboratory of Cell and Molecular Signaling, Center for Biomedical Research at The Queen’s Medical Center and John A. Burns 
School of Medicine at the University of Hawaii, Honolulu, HI 96813
TRPM7 is a Ca2+- and Mg2+-permeable cation channel that also contains a protein kinase domain. While there is 
general consensus that the channel is inhibited by free intracellular Mg2+, the functional roles of intracellular 
  levels of Mg·ATP and the kinase domain in regulating TRPM7 channel activity have been discussed controversially. 
To obtain insight into these issues, we have determined the effect of purine and pyrimidine magnesium nucleotides 
on TRPM7 currents and investigated the possible involvement of the channel’s kinase domain in mediating them. 
We report here that physiological Mg·ATP concentrations can inhibit TRPM7 channels and strongly enhance the 
channel blocking effi  cacy of free Mg2+. Mg·ADP, but not AMP, had similar, albeit smaller effects, indicating a dou-
ble protection against possible Mg2+ and Ca2+ overfl  ow during variations of cell energy levels. Furthermore, nearly 
all Mg-nucleotides were able to inhibit TRPM7 activity to varying degrees with the following rank in potency: 
ATP > TTP > CTP ≥ GTP ≥ UTP > ITP ≈ free Mg2+ alone. These nucleotides also enhanced TRPM7 inhibition by 
free Mg2+, suggesting the presence of two interacting binding sites that jointly regulate TRPM7 channel activity. 
  Finally, the nucleotide-mediated inhibition was lost in phosphotransferase-defi  cient single-point mutants of TRPM7, 
while the Mg2+-dependent regulation was retained with reduced effi  cacy. Interestingly, truncated mutant channels 
with a complete deletion of the kinase domain regained Mg·NTP sensitivity; however, this inhibition did not 
  discriminate between nucleotide species, suggesting that the COOH-terminal truncation exposes the previously 
inaccessible Mg2+ binding site to Mg-nucleotide binding without imparting nucleotide specifi  city. We conclude 
that the nucleotide-dependent regulation of TRPM7 is mediated by the nucleotide binding site on the channel’s 
endogenous kinase domain and interacts synergistically with a Mg2+ binding site extrinsic to that domain.
INTRODUCTION
TRPM7 is a widely expressed member of the melastatin-
related subfamily of TRPM proteins (for recent reviews 
see Fleig and Penner, 2004; Harteneck, 2005) that com-
bines structural elements of both an ion channel and a 
protein kinase (Nadler et al., 2001; Runnels et al., 2001; 
Ryazanova et al., 2001; Yamaguchi et al., 2001). It rep-
resents the only ion channel known that is essential 
for cellular viability (Nadler et al., 2001). Signifi  cant 
efforts have been made to characterize the properties 
of both the channel and kinase activities of TRPM7 as 
well as their possible interdependence in mediating 
physiological responses. However, contrasting accounts 
of practically every biophysical property and the regula-
tory mechanisms that control channel activity have 
been presented.
For example, Clapham and colleagues have classifi  ed 
TRPM7 as a nonselective cation channel that is activated 
by ATP via its kinase domain (Runnels et al., 2001), 
whereas our laboratory has described it as a highly se-
lective divalent cation channel conducting both Mg2+ 
and Ca2+ ions that is constitutively active at low levels 
and regulated by intracellular levels of free Mg2+ and 
Mg-nucleotides (Nadler et al., 2001). Subsequent work 
has established that TRPM7 is indeed a divalent-specifi  c 
cation channel that conducts essentially all physiologi-
cal as well several toxic divalent cations (Monteilh-Zoller 
et al., 2003). It is now also clear that free intracellular 
Mg2+ can regulate TRPM7 activity (Schmitz et al., 2003; 
Takezawa et al., 2004; Matsushita et al., 2005), and the 
reported ATP-dependent activation of TRPM7 (Runnels 
et al., 2001) was in fact due to the use of Na·ATP, which 
reduced free Mg2+. However, the regulation by Mg2+-
nucleotides proposed by our laboratory has been chal-
lenged by Cahalan and colleagues. While they confi  rmed 
the original observation that TRPM7 can be   inhibited 
by Mg·ATP in the presence of EGTA, they also reported 
that this inhibition is lost when using a strong Mg2+ che-
lator, HEDTA, leading them to conclude that the Mg2+-
nucleotide effect can be explained by free Mg2+ alone 
(Kozak and Cahalan, 2003).
A further point of contention is the role of the kinase 
domain in regulating channel activity. Clapham and 
colleagues suggested that the kinase domain is essential 
for channel activation, since two point mutations 
  designed to disrupt the kinase’s phosphotransferase 
  activity resulted in nonfunctional channels (Runnels 
et al., 2001). However, based on the crystal structure of 
Correspondence to Andrea Fleig: afl  eig@hawaii.edu
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TRPM7’s kinase domain (Yamaguchi et al., 2001), one 
of the mutations was considered to be inconsequential 
for phosphotransferase activity and the other mutation 
was found to express a fully functional channel protein 
(Schmitz et al., 2003; Matsushita et al., 2005), suggest-
ing that a functional kinase is not essential for channel 
activity. In fact, we found that even a full deletion of 
TRPM7’s kinase domain still produced functional ion 
channels (Schmitz et al., 2003), although another study 
using a different truncation mutant failed to observe 
any channel activity (Matsushita et al., 2005). While our 
previous work suggests that the phosphotransferase-
  defi  cient forms of the protein do affect TRPM7 channel 
activity by rendering them less sensitive to inhibition by 
Mg2+ and Mg·ATP (Schmitz et al., 2003; Takezawa et al., 
2004), Nairn and colleagues suggested that the kinase 
domain of TRPM7 is completely ineffectual in modu-
lating channel activity (Kozak and Cahalan, 2003; 
  Matsushita et al., 2005).
Finally, there is a debate about the reported modu-
lation of TRPM7 by phospholipids. Clapham and 
colleagues proposed that TRPM7’s channel activity re-
quires phosphatidylinositol bisphosphate (PIP2) and 
its depletion via PLC-mediated hydrolysis renders it 
  inactive. Our own work challenged this interpretation in 
that we observed no signs of PLC-mediated breakdown 
of PIP2 in cells that overexpress TRPM7, consistent 
with and presumably due to the fact that TRPM7 binds 
to PLC (Runnels et al., 2002). Instead, we proposed that 
TRPM7 is up-regulated via the PKA pathway and this 
modulation requires a functional TRPM7 kinase do-
main (Takezawa et al., 2004).
In the present study, we have attempted to resolve 
some of the controversial aspects of TRPM7 regula-
tion by a comprehensive assessment of the inhibi-
tory effects of free Mg2+ and Mg-nucleotides, both 
individually and in combination, on wild-type and 
phosphotransferase-defi   cient channels. Our results 
suggest a synergistic inhibition of TRPM7 activity by 
both Mg2+ and Mg-nucleotides that is mediated by two 
distinct sites, where the Mg2+ binding site is extrin-
sic and the nucleotide binding site is intrinsic to the 
TRPM7 kinase domain.
MATERIALS AND METHODS
Cells
HEK-293 cells stably transfected with the HA-tagged human 
TRPM7 construct as previously described (for details see Schmitz 
et al., 2003) were grown in DMEM medium supplemented with 
10% FBS, blasticidin (5 μg/ml), and zeocin (0.4 mg/ml). TRPM7 
expression was induced 1 d before use by adding 1 μg/ml tetracy-
cline to the culture medium. Patch-clamp measurements were 
performed 16–24 h post-induction (for details see Nadler et al., 
2001). The phosphotransferase activity-defi  cient point mutants 
of TRPM7, K1648R, and G1799D, as well as the ∆-kinase mutant 
were based on the human TRPM7 construct (for details see 
Schmitz et al., 2003). TRPM7 mutant expression was induced the 
day preceding the experiment by adding 1 μg/ml tetracycline to 
the culture medium. Patch-clamp measurements were performed 
12–16 h post-induction for the point mutants and 18–24 h post-
induction for the ∆-kinase mutant.
Solutions
Cells grown on glass coverslips were transferred to the recording 
chamber and kept in a standard modifi  ed Ringer’s solution of the 
following composition (in mM): NaCl 140, KCl 2.8, CaCl2 1, MgCl2 
2, glucose 10, HEPES·NaOH 10, pH 7.2, with osmolarity typically 
ranging from 295 to 325 mOsm. Intracellular pipette-fi  lling solu-
tions contained (in mM) Cs-glutamate 140, NaCl 8, Cs-BAPTA 10, 
HEPES·CsOH 10, pH 7.2 adjusted with CsOH. In some experi-
ments, BAPTA was omitted and in others it was replaced by HEDTA 
and/or EGTA. Since TRPM7 activity is affected by both extra- and 
intracellular pH (Gwanyanya et al., 2004; Jiang et al., 2005; Kozak 
et al., 2005), particular care was taken to adjust pH. Mg-ade  nosine 
nucleotide concentrations and free intracellular [Mg2+]i were 
calculated with WebMaxC standard (12/31/2003, http://www.
stanford.edu/~cpatton/webmaxcS.htm; the binding constants 
are derived from the NIST database at http://www.nist.gov/srd/
nist46.htm and their values are listed at http://www.stanford.
edu/~cpatton/xlsconstants.htm). All other Mg-nucleotides were 
used at concentrations matching the corresponding Mg-adenosine 
  nucleotide concentration. The solutions were made using appro-
priate mixtures of magnesium chloride and sodium-nucleotides. 
All chemicals used were purchased from Sigma-Aldrich. For a 
  detailed list of all ingredients for the various intracellular solutions 
used in this study, see online supplemental material (available at 
http://www.jgp.org/cgi/content/full/jgp.200509410/DC1).
Patch-clamp Experiments
Patch-clamp experiments were performed in the tight-seal whole-cell 
confi  guration at 21–25°C. High-resolution current recordings were 
acquired by a computer-based patch-clamp amplifi  er system (EPC-9, 
HEKA, Lambrecht). Patch pipettes had resistances between 2 and 
4 MΩ after fi  lling with the standard intracellular solution. Immedi-
ately following establishment of the whole-cell confi  guration, voltage 
ramps of 50 ms duration spanning the voltage range of −100 to 
+100 mV were delivered from a holding potential of 0 mV at a rate 
of 0.5 Hz over a period of 600 s. All voltages were corrected for a liq-
uid junction potential of 10 mV between external and internal solu-
tions because of glutamate use as intracellular anion. Currents were 
fi  ltered at 2.9 kHz and digitized at 100-μs intervals. Capacitive cur-
rents and series resistance were determined and corrected before 
each voltage ramp using the automatic capacitance compensation of 
the EPC-9. The low-resolution temporal development of membrane 
currents was assessed by extracting the current amplitude at +80 mV 
from individual ramp current records. Where applicable, statistical 
errors of averaged data are given as means ± SEM with n determina-
tions and statistical signifi  cance was assessed by Student’s t test. The 
currents were normalized with the capacitance measurement imme-
diately after break-in in order to remove cell size variations. Dose 
  response curves were calculated using the function f(x) = (Ymax * 
(1/(1 + (IC50/x)n))), where Ymax is the maximal normalized cur-
rent, IC50 is the Mg2+ or Mg-nucleotide concentration at which inhi-
bition is half maximal, x is the Mg2+ or Mg-nucleotide concentration, 
and n is the Hill coeffi  cient. The Hill coeffi  cient for all dose re-
sponses was very close to 2. It was systematically fi  xed at this value 
in order to compare the different dose responses. Dose–response 
curves were normalized to unity by dividing by Ymax.
Online Supplemental Material
The online supplemental material elaborates on the exact intra-
cellular solution compositions used, sorted by fi  gure (available at 
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RESULTS
TRPM7 Is Inhibited by Free Mg2+, ATP, and ADP, 
but Not by AMP
In an earlier study, we have shown that Mg·ATP and free 
Mg2+ both inhibit TRPM7 channels (Nadler et al., 2001). 
To further assess the regulation of TRPM7-mediated 
  divalent transport, we performed whole-cell patch-
clamp experiments in HEK-293 cells overexpressing 
  human TRPM7 in which we introduced various concen-
trations of free Mg2+ and nucleotides. In a fi  rst set of 
control experiments, we established a dose–response 
curve for free Mg2+ by perfusing cells with intracellular 
solutions containing defi  ned levels of free Mg2+ in the 
absence of any added nucleotides. As can be seen in 
Fig. 2 A, increasing concentrations of Mg2+ caused a 
dose-dependent inhibition of TRPM7 currents. The half-
maximal inhibition derived from the dose–response 
curve depicted in Fig. 2 B was 720 ± 79 μM (n = 6–10). 
In a second set of control experiments we tested various 
adenosine nucleotides for inhibition of TRPM7. With 
6  mM Na-ATP, Na-ADP, and Na-AMP in the internal 
  solution and no added Mg2+, TRPM7 currents activate 
quickly and reach a plateau after 100–200 s (Figs. 1, A–D).
Whole-cell currents were large for all three nucleo-
tides, but there was a decrease in the peak amplitudes 
obtained with ADP (136 ± 32 pA/pF; n = 4) and AMP 
(110 ± 25 pA/pF; n = 5) compared with ATP (173 ± 25 
pA/pF; n = 9). This order of potency correlates with 
the magnesium-complexing strength of the nucleotide 
species, indicating that, although no Mg2+ was present 
in the pipette solution, intracellular Mg2+ levels may be 
slightly different due to intracellular Mg2+ mobilization 
or Mg2+ infl   ux through TRPM7 itself. Thus, Mg2+ 
  binding effi  cacy of the nucleotides may affect TRPM7 
activity via buffering free Mg2+, with ATP being the most 
and AMP being the least effi  cient.
When intracellular solutions were buffered to physio-
logical levels of Mg ( 800  μM), ATP and ADP both 
strongly inhibited TRPM7 currents (Fig. 1, A and B), 
whereas AMP was completely ineffective at doing so (Fig. 
1 C). These fi  ndings suggest that in the presence of free 
Mg2+, Mg·ATP and Mg·ADP, but not AMP (which does 
not complex Mg2+), strongly affect TRPM7 activity. This 
inhibition by Mg-nucleotides appears to be synergistic 
with free Mg2+, since the same level of free Mg2+ in com-
bination with AMP produces only a moderate reduction 
in current amplitude compared with the combined 
presence of ATP/ADP and free Mg2+.
To assess the inhibition of TRPM7 ion channels by 
Mg·ATP and free Mg2+ quantitatively, we perfused 
cells with a fi  xed Mg·ATP concentration of 6 mM and 
varied the free Mg2+ concentration. As illustrated in 
Fig. 1 (E and F), TRPM7 currents were progressively 
inhibited by free Mg2+ concentrations of 70 μM or 
higher. The inhibition of the current was already 
nearly complete at 210 μM free Mg2+. The calculated 
IC50 for free Mg2+ in the presence of a fi  xed Mg·ATP 
concentration of 6 mM was 130 ± 18 μM (Fig. 1 F). By 
comparison, in the absence of Mg·ATP, the free Mg2+ 
Figure 1.  Inhibition of 
TRPM7 by ATP, ADP and 
free Mg2+, but not by 
AMP. Whole cell currents 
were recorded in HEK-
293 cells induced to over-
express human TRPM7. 
Cs-BAPTA was used as in-
tracellular calcium buffer. 
(A) Cells were perfused 
with 6 mM ATP and no 
Mg2+ ( n  = 4) or 6 mM 
Mg·ATP and 790 μM free 
Mg2+ (n = 7). (B) Cells 
were perfused with 6 mM 
ADP and no Mg (n = 5) 
or 6 mM Mg·ADP and   
780 μM free Mg2+ (n = 
6). (C) Cells were per-
fused with 6 mM AMP 
and no Mg (n  = 9) or 
6 mM AMP and 750 μM 
free Mg2+ ( n  = 5). (D) 
Representative current–
voltage (I/V) relationships for TRPM7, in the conditions described above (A–C). All I/V relationships were taken at 200 s and were de-
rived from a high-resolution current record in response to a voltage ramp of 50 ms duration that ranged from −100 mV to +100 mV. 
(E) Inhibition of TRPM7 currents by 6 mM Mg·ATP and increasing free Mg2+ concentrations (n = 4–8). (F) Dose–response curve 
of TRPM7 current inhibition by 6 mM Mg·ATP and increasing free Mg2+ concentrations (0, 70, 120, 160, 210, 420, 790, 1,600, and 
3,200 μM) at 200 s (n = 4–8). The best fi  t was obtained with a Hill coeffi  cient close to 2 and was therefore fi  xed at that value.424 TRPM7 Nucleotide Regulation via its Kinase Domain
concentration   necessary to block TRPM7 currents by 
50% is >700 μM (Fig. 2 B). [ID]FIG2[ID] These results suggest that 
a cross-talk exists between Mg-nucleotides and free 
  intracellular Mg2+.
Mg·ATP and Free Mg2+ Regulate TRPM7 Ion Channels 
in Synergy
In a further set of experiments, we determined how 
both Mg·ATP and free Mg2+ coregulate TRPM7 chan-
nel activity. We measured the inhibition of TRPM7 cur-
rents under increasing Mg·ATP concentrations while 
maintaining the free Mg2+ concentration fi  xed to low, 
physiological, or high levels (210, 790, or 1600 μM, 
  respectively). As demonstrated in Fig. 2 C, increasing 
Mg·ATP concentrations strongly inhibited TRPM7 cur-
rents when free intracellular Mg2+ was fi  xed to  800 μM 
(n = 4–7) with an IC50 of 2 ± 0.76 mM (Fig. 2 D). The 
biggest changes were seen over physiological Mg·ATP 
concentrations between 2 and 4 mM Mg·ATP. This 
  behavior was also evident at lower and higher Mg2+ con-
centration (Fig. 2 E). In summary, the calculated IC50 
values for Mg·ATP inhibition of TRPM7 currents de-
creased with increasing levels of free Mg2+ from 
3.33 ± 0.49 mM (n = 5–12) at  200 μM free Mg2+ to 
2 ± 0.76 mM (n = 4–7) at physiological free Mg2+ of 
 800 μM and down to 1.62 ± 0.18 mM (n = 5–7) at 
 1,600 μM free Mg2+ (Table I and Fig. 2 E). [ID]TBL1[I D] All dose 
response curves showed a Hill coeffi  cient very close to 
2, suggesting the need of two cooperative binding sites 
to cause inhibition of the channel.
We should point out that we have prepared dose–
  response curves at different time points (100, 200, 300, 
400, and 600 s) and, while their IC50 varied <10% with-
out affecting the apparent cooperativity (unpublished 
data), we decided that the most adequate time point 
was at 200 s for the following reasons. The most important 
consideration is based on the equilibration time con-
stant of the relevant molecules after going whole cell, 
Figure 2.  Inhibition of TRPM7 by Mg·ATP and free 
Mg2+. Whole-cell currents were recorded in HEK-
293 cells induced to overexpress human TRPM7. 
Cs-BAPTA was used as buffer. (A) Cells were per-
fused with increasing concentrations of free Mg2+ 
(n = 6–10). (B) Dose–response curve for the inhibi-
tion of TRPM7 current by increasing free Mg2+ con-
centrations (0, 70, 210, 780, 1,270, 1,600, and 3,200 
μM). Data points correspond to average and nor-
malized current amplitudes measured at + 80 mV 
after 200 s of whole-cell recording, plotted as a func-
tion of free Mg2+ concentration (n = 6–10). The 
best fi  t was obtained by a Hill coeffi  cient close to 2 
and was therefore fi  xed at that value. The calculated 
IC50 value for free Mg2+ concentration inhibition of 
TRPM7 current is 720 ± 79 μM. (C) Cells were per-
fused with increasing concentrations of Mg·ATP (in 
this example, the free Mg2+ concentration was fi  xed 
to around 780 μM; n = 4–7). (D) Dose–response 
curve for the inhibition of TRPM7 current by in-
creasing Mg·ATP concentrations (0, 1, 2, 4, and 
6 mM Mg·ATP, free Mg2+ concentrations were fi  xed 
in this example around 790 μM). Data points corre-
spond to average and normalized current ampli-
tudes measured at +80 mV after 200 s of whole-cell 
recording, plotted as a function of Mg·ATP concen-
tration (n = 4–7). The best fi  t was obtained by a Hill 
coeffi  cient close to 2 and was therefore fi  xed at that 
value. The calculated IC50 value for ATP concen-
tration inhibition of TRPM7 current under physio-
logical free Mg2+ (790 μM) is 2 ± 0.7 mM. (E) 
Comparison of dose–response curves as a function 
of Mg·ATP concentrations at different fi  xed  free 
Mg2+ concentrations (210, 790, and 1,600 μM). Data 
points from the 790 μM dose–response curve were 
omitted for clarity as they are presented in B. Each 
dose–response was   calculated as in B and normalized 
to 1 by dividing with Ymax (n = 4–12). (F) Comparison 
of dose–response curves as a function of free Mg2+ 
concentrations at different fi  xed Mg·ATP concentra-
tions (0, 1, 2, 4, and 6 mM). Each dose–response curve was calculated as in Fig. 1 F and normalized to 1 by dividing with Ymax (n = 4–8). 
All the Hill coeffi  cients of the dose–response curves in C and D were fi  xed to 2.  Demeuse et al.  425
which is estimated to be  6 s for Mg2+,  90 s for ATP, 
and   120 s for BAPTA/HEDTA (Pusch and Neher, 
1988). 200 s would allow most factors supplied by the 
  pipette solution to be close to equilibrium. Later time 
points could be less reliable, since the perfusion of the 
cytosol may lead to washout of larger proteins or factors 
that may affect TRPM7 (e.g., cytoskeleton, G proteins, 
enzymes, calmodulin, polyamines). In fact, we often ob-
serve a slow change of TRPM7 currents after  300 s 
that manifests itself in slow inactivation when currents 
are large or an increase when currents are strongly 
  inhibited (see e.g., Fig. 1, A and B, and Fig. 2 A). Thus, 
it seems that the large increase in current that occurs 
after 200 s in Fig. 2 A at 3,200 μM free Mg2+ is unrelated 
to changes in Mg2+ or Mg-nucleotide levels (both of 
which we believe to have achieved nearly steady-state 
levels by this time), but instead refl  ects some other fac-
tor that has not yet been identifi  ed.
We next performed complementary experiments in 
which we increased free Mg2+ concentrations (210, 780, 
1,600, and 3,200 μM) at fi  xed levels of Mg·ATP (0, 1, 2, 
4, or 6 mM). As described above, TRPM7 currents were 
inhibited by free Mg2+ in the absence of ATP (Fig. 2, A 
and B) with an IC50 of 720 ± 79 μM (n = 6–10). Addi-
tion of Mg·ATP gradually increased the effi  cacy of Mg2+ 
to inhibit TRPM7 up to 4 mM Mg·ATP (Fig. 2 F), where 
the IC50 of inhibition by free Mg2+ was decreased seven-
fold (110 ± 7 μM; n = 5–7). Higher concentrations of 
Mg·ATP did not further decrease the IC50 of inhibition 
by free Mg2+. The individual IC50 values under the vari-
ous experimental conditions are listed numerically in 
Table I. From these results, it would seem that free Mg2+ 
can inhibit TRPM7 without requiring Mg·ATP, whereas 
Mg·ATP does require the additional presence of free 
Mg2+. In physiological terms, however, where free Mg2+ 
levels are relatively constant at 0.5–1 mM, Mg·ATP 
would likely play a dominant role in setting TRPM7 
magnitude, since physiological levels of Mg·ATP around 
2–4 mM would block >80% of TRPM7 current. In any 
case, Mg·ATP and free Mg2+ are both likely to regulate 
TRPM7 ion channels in synergy.
Mg·ATP Inhibits TRPM7 Independently 
of the Ca2+/Mg2+ Chelator
An important question regarding the effi  cacy  of 
Mg·ATP to suppress TRPM7 was raised by a report that 
found when using HEDTA to buffer free Mg2+ to 270 
μM, even high concentrations of 5 mM Mg·ATP were 
completely ineffective in suppressing TRPM7 above 
and beyond the inhibition seen when Mg2+ was buff-
ered to the same level with EGTA (Kozak and   Cahalan, 
2003). Since our previous experiments were all per-
formed with BAPTA, we fi  rst performed experiments in 
which BAPTA was   replaced by HEDTA. We observed 
that HEDTA in the absence of added Mg2+ caused a 
rapid and massive activation of TRPM7 that initially 
surpassed the activation seen with BAPTA (Fig. 3 A), 
which was not unexpected given the stronger Mg2+ 
chelation of HEDTA. [ID]FIG3[] Interestingly, however, the cur-
rent inactivated after reaching a peak and even  tually 
decayed to levels below those seen with BAPTA. 
  Addition of Mg2+ at a concentration of 3.2 mM strongly 
inhibited TRPM7 activity to very low levels and average 
currents observed with BAPTA and HEDTA were essen-
tially indistinguishable (Fig. 3 A).
We next sought to replicate the experimental results 
obtained by Kozak and Cahalan (2003), who reported 
the complete loss of Mg·ATP sensitivity of TRPM7 when 
using a mixture of 3 mM EGTA and 2.5 mM HEDTA 
compared with 12 mM EGTA, where both solutions 
were adjusted to a free Mg2+ of 270 μM. They observed 
that both solutions suppressed TRPM7 by  70–75% 
compared with solutions that lack Mg2+ and nucleotides 
and interpreted this as evidence that Mg·ATP does not 
provide any additional inhibition beyond that induced 
by Mg2+ alone. Fig. 3 B shows the average currents we 
observed when using intracellular solutions as used 
by Kozak and Cahalan (2003). In reasonable agree-
ment with the above study, we saw  80% inhibition of 
TRPM7 currents by the internal solutions containing 
3 mM EGTA and 2.5 mM HEDTA and the additional 
presence of 5 mM Mg·ATP. However, we were not able 
to suppress TRPM7 to the same degree when using 12 
mM EGTA to buffer free Mg2+ at 270 μM (see also our 
dose–response curve in Fig. 2 B). It should be noted 
that the Kozak and Cahalan study used the same soft-
ware as we do to cal  culate free Mg2+. However, software 
versions before 10/2004 were affl  icted by a problem 
with binding constants involving ATP (for details see 
http://www.stanford.edu/~cpatton/mcn072802.htm), 
and therefore the ATP-containing solution used by 
  Kozak and Cahalan was not buffered at calculated levels 
of 270 μM free Mg2+ as the EGTA solution, but rather 
at  360 μM. We decided to further probe the inhibi-
tory effect of Mg·ATP by increasing HEDTA concentra-
tions to 10 mM, reducing free Mg2+ to 210 μM, and 
using physiological levels of Mg·ATP of 4 mM. As il-
lustrated in Fig. 3 C, and consistent with Fig. 3 B, the 
TABLE I
Inhibition of TRPM7 by Mg·ATP and Free Mg2+
Nucleotide IC50 (μM free Mg2+) [Free Mg2+]I C 50 (mM Mg·ATP)
None 720 ± 79 (n = 6–10) 210 μM 3.33 ± 0.49 (n = 5–12)
1 mM MgATP 457 ± 206 (n = 5–15) 790 μM 2.0 ± 0.76 (n = 4–7)
2 mM MgATP 256 ± 66 (n = 5) 1600 μM 1.62 ± 0.18 (n = 5–7)
4 mM MgATP 110 ± 7 (n = 4–8)
6 mM MgATP 128 ± 18 (n = 4–8)
Comparison of half maximal inhibitory concentrations (IC50) of free Mg2+ 
at fi   xed Mg·ATP concentrations (left two columns) and IC50 values of 
Mg·ATP at fi   xed free Mg2+ concentrations (right two columns). The 
whole-cell currents were recorded in HEK-293 cells induced to overexpress   
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low   concentration of 210 μM free Mg2+ by itself had 
no signifi  cant inhibitory effect on the maximal TRPM7 
current, being similar to that observed at 0 Mg2+ (com-
pare Fig. 3 A). Remarkably, though, the presence of 
some free Mg2+ prevented the marked inactivation we 
observed in 0 Mg2+ conditions, resulting in a sustained 
activation of TRPM7 current. This might suggest that 
Mg2+, while acting as an inhibitor of TRPM7, is also re-
quired to maintain a sustained current. The additional 
presence of 4 mM Mg·ATP, even under these more 
stringent experimental conditions, clearly produced 
a strong suppression of TRPM7. We therefore cannot 
support the results and inter  pretation put forward by 
Kozak and   Cahalan and we conclude that TRPM7 is in 
fact subject to Mg-  nucleotide–dependent regulation.
Regardless of whether or not the inhibition of 
TRPM7 by Mg·ATP is dependent on the Ca2+/Mg2+ 
chelator used, a more relevant question is whether the 
effect   occurs under physiological conditions, i.e., in 
the absence of any exogenous chelators. Fig. 3 D dem-
onstrates that this is indeed the case. Here, the intra-
cellular solution contained no chelator and free Mg2+ 
was set to near physiological levels of 650 μM. The ad-
dition of physiological levels of 4 mM Mg·ATP caused 
a strong suppression of TRPM7 currents, suggesting 
that Mg·ATP represents a physiological regulator of 
TRPM7 activity.
A recent study reported a surprisingly low effi  cacy of 
free Mg2+ to inhibit TRPM7 (Hermosura et al., 2005). 
The authors found that 1 mM added free Mg2+ reduced 
TRPM7 currents by <20%, whereas all published work 
on either heterologous or native TRPM7 demonstrates 
that this concentration of free Mg2+ inhibits the current 
by at least 50%. However, the experimental conditions 
in all of these studies are slightly different and may ac-
count for the discrepancy. Since Hermosura et al. used 
the very same TRPM7-overexpressing HEK-293 cells we 
used in the present study, we determined the effi  cacy 
of free Mg2+ in blocking TRPM7 using the same ex-
perimental conditions the authors of the previous study 
  employed.   However, as illustrated in Fig. 3 E, we were 
unable to reproduce and confi   rm the experimental 
  results of Hermosura et al. regarding the Mg2+-medi-
ated inhibition of WT TRPM7. In our hands, perfusing 
cells with 1 mM added Mg2+ in the presence of 10 mM 
EGTA plus 2.5 mM Ca2+ (free [Ca2+]i ≈ 55 nM) pro-
duced a 50% inhibition of TRPM7 currents compared 
with the 0 Mg2+ control, which is very similar to the 
Figure 3.  Mg2+ and Mg·ATP inhibi-
tion of TRPM7 currents is inde-
pendent of the buffer. Whole-cell 
currents were recorded in HEK-293 
cells induced to overexpress human 
TRPM7. The currents were normal-
ized by the capacitance of the cells 
recorded at break-in. (A) Compari-
son of HEDTA and BAPTA on 
TRPM7 current inhibition by Mg2+. 
Cells were perfused with 10 mM of 
either buffer without added Mg2+ or 
with 3.2 mM free Mg2+ (n = 4–8). 
(B) Mg·ATP block of TRPM7 cur-
rent using the conditions published 
by Kozak and Cahalan (2003). The 
cells were perfused with 12 mM 
EGTA and 0.5 mM MgCl2 (270 μM 
free Mg2+; n = 5) or with 2.5 mM 
HEDTA, 3 mM EGTA, 4 mM 
Mg·ATP, 360 μM free Mg2+ (n = 6). 
Mg·ATP block is clearly shown. Left 
axis labeling same as in A. (C) Com-
parison of HEDTA and BAPTA on 
TRPM7 current inhibition by 
Mg·ATP. Cells were perfused with 
10 mM of either buffer with a fi  xed 
concentration of 210 μM free Mg2+ 
with or without 4 mM Mg·ATP (n = 
5–8). Left axis labeling same as 
in A. (D) Typical example of Mg·ATP 
block of TRPM7 current in the 
  absence of any Mg2+ or Ca2+ chelator and under physiologically relevant magnesium concentrations. The cells were perfused with a 
fi  xed concentration of 650 μM free Mg with or without 4 mM Mg·ATP (n = 6). (E) Mg2+ inhibition of TRPM7 current with EGTA buffering. 
Cells were perfused with 10 mM of EGTA and 2.5 mM Ca2+ (≈55 nM free) without added Mg2+ or with 0.5 or 1 mM MgCl2 (370 and 
740 μM free Mg2+, respectively (n = 7–11).  Demeuse et al.  427
  degree of inhibition we and others have observed un-
der a variety of experimental conditions.
NTP and NDP Inhibit TRPM7 Currents 
with Varying Efﬁ  cacy
We next asked whether the inhibitory effect was specifi  c 
for adenosine nucleotides and tested for the ability of 
other nucleotides for possible regulation of TRPM7. We 
fi  rst perfused cells with guanosine nucleotides (6 mM 
Mg·GTP) and increasing free Mg2+ concentrations. 
As illustrated in Fig. 4 A, this nucleotide produced a 
strong inhibition of TRPM7 currents (n = 5–12).[ID]FIG4[ID] At 
physiological free Mg2+ concentrations, the response to 
GTP was biphasic in that the nucleotide seemed to fi  rst 
potentiate the current before blocking it. The calcu-
lated IC50 of free Mg2+ in the presence of 6 mM Mg·GTP 
was 340 ± 95 μM (Fig. 4 B). We then extended this anal-
ysis to other purine- and pyrimidine-based triphosphates 
(ITP, UTP, TTP, and CTP). Except for ITP, each of these 
nucleotides showed a potentiation of TRPM7 inhibition 
by free Mg2+, with ATP being the most potent. Based on 
the IC50 values for 6 mM Mg·NTP, the sequence of po-
tency was as follows: ATP > TTP > CTP ≥ GTP ≥ UTP 
> ITP ≈ free Mg2+ alone (Fig. 4 C and Table II). [ID]TBL2[
We then assessed the effect of 6 mM nucleotide di-
phosphates within the same range of free Mg2+ concen-
trations. All NDP tested enhanced the block of TRPM7 
currents by free Mg2+, except CDP. Fig. 4 D shows the 
ADP effect as an example. However, each NDP was 
somewhat less potent than its corresponding NTP, with 
the exception of IDP. Based on the IC50 values for 6 mM 
Mg·NDP, the sequence of potency was as follows: IDP ≥ 
ADP > TDP = GDP > UDP ≥ CDP ≈ free Mg alone 
(Fig. 4 F and Table II). The dose response behavior of 
IDP, however, may not be entirely accurate. The current 
amplitudes measured with 6 mM Mg·IDP and 210 μM 
free Mg2+ conditions were very low compared with 
higher free Mg2+ concentrations. As commercial IDP is 
produced from ADP, it is possible that ADP contamina-
tions were present in the solution used. Considering 
that we had to add very high Na·IDP concentrations 
( 31 mM) to obtain 210 μM free Mg2+ and 6 mM 
Figure 4.  Di- and triphosphate nucleotides inhibit TRPM7 currents. Whole cell currents were recorded in HEK-293 cells induced to 
overexpress human TRPM7. Cs-BAPTA was used as intracellular calcium buffer. (A) Typical example of TRPM7 current inhibition by 
NTP. Cells were perfused with 6 mM Mg·GTP and increasing free Mg2+ concentrations (n = 5–12). (B) Dose–response curve of TRPM7 
current inhibition by 6 mM Mg·GTP and increasing free Mg2+ concentrations (0, 160, 420, 790, 1,600, and 3,200 μM). Data points cor-
respond to average and normalized current amplitudes measured at +80 mV after 200 s of whole-cell recording, plotted as a function 
of free Mg2+ concentration (n = 5–12). The calculated IC50 value for free Mg2+ concentration in the presence of 6 mM Mg·GTP is 
340 ± 95 μM. (C) Comparison of dose–response curves as a function of free Mg concentrations for different NTP. Each dose response 
was calculated as in B and normalized to 1 by dividing with Ymax. (D) Typical example of TRPM7 current inhibition by ADP. Cells were 
  perfused with 6 mM Mg·ADP and increasing free Mg2+ concentrations (n = 6–15). (E) Dose–response curve of TRPM7 current inhibition 
by 6 mM Mg·ADP and increasing free Mg2+ concentrations (0, 160, 210, 780, and 1,600 μM). Data points correspond to average and 
normalized current amplitudes measured at +80 mV after 200 s of whole-cell recording, plotted as a function of free Mg2+ concentration 
(n = 6–15). The calculated IC50 value for free Mg2+ concentration in the presence of 6 mM Mg·ADP is 250 ± 81 μM. (F) Comparison 
of dose–response curves as a function of free Mg2+ concentration for different NDP. Each dose–response was calculated as in E and 
  normalized to 1 by dividing with Ymax. All the Hill coeffi  cients of the dose–response curves were fi  xed to 2.428 TRPM7 Nucleotide Regulation via its Kinase Domain
Mg·IDP, an ADP contamination of just 2–3% would 
amount to  1 mM of ADP in the solution and could 
therefore account for the observed inhibition. From 
these experiments, we propose that ATP and ADP are 
the most potent nucleotides as inhibitors of TRPM7 
currents. As most nucleotides tested showed an in-
crease in Mg2+ inhibition effi  cacy, we conclude that 
ATP, ADP, and free Mg2+ act in synergy to regulate 
TRPM7. The cellular levels of these three players will 
therefore regulate very precisely the entry of divalents via 
TRPM7 channels.
Mg·ATP Inhibition of TRPM7 Requires 
a Functional Kinase Domain
The difference of TRPM7 current inhibition between 
Mg·ATP and Mg·ITP (Fig. 4 C) came as a surprise, since 
these molecules are chemically very similar. It is not 
likely due to differences in free Mg2+ concentration, 
since increasing free Mg2+ concentration to 1,600 μM 
still exhibited a difference in the suppression of the cur-
rent between 6 mM Mg·ATP and 6 mM Mg·ITP (Fig. 5 B). [ID]FIG5[ 
The fact that TRPM7 can discriminate between the two 
nucleotides suggests a particularly specifi  c inhibitory 
action of Mg·ATP that might be conferred by the chan-
nel’s endogenous kinase domain. As we already de-
monstrated that phosphotranferase activity-defi  cient 
mutants of TRPM7 exhibit altered Mg2+ and Mg·ATP-
dependant suppression of basal channel activity 
(Schmitz et al., 2003), we wondered if this difference 
between nucleotides would still occur in cells over-
expressing the phosphotransferase activity-defi  cient 
protein. We tested the effect of Mg-nucleotides on three 
different HEK-293 cell lines overexpressing proteins 
that had been modifi  ed by point mutations K1648R and 
G1977D as well as a truncation mutant with a complete 
deletion of the kinase domain (∆-kinase). The fi  rst 
point mutation targets a strictly conserved lysine resi-
due in α-kinases and protein kinases that interacts with 
the α and β phosphates of ATP. This lysine is absolutely 
essential for catalytic activity (Yamaguchi et al., 2001). 
The second mutation is directed toward a conserved 
COOH-terminal glycine-rich motif that is thought to 
be involved in substrate recognition. It is located 
within the region corresponding to the activation loop 
of classical kinases (Yamaguchi et al., 2001). All three 
mutants produced membrane currents that showed 
the same characteristic current–voltage relationships as 
wild-type TRPM7. While the two point mutants also had 
similar current amplitudes as wt TRPM7, the ∆-kinase 
construct yielded signifi   cantly smaller currents that 
  inactivated relatively quickly, as previously described 
(Schmitz et al., 2003).
When exposed to the various nucleotides, the 
K1648R mutation clearly changed the NTP’s ability to 
regulate TRPM7 (Fig. 5 C). In this mutant, there was no 
longer a difference between ATP, GTP, and ITP or the 
control solution containing 210 μM free Mg2+ alone. 
This point mutation therefore is no longer susceptible 
to selective inhibition of channel activity by either 
Mg·ATP or Mg·GTP. Performing the same experiment 
in cells overexpressing the mutant TRPM7 protein with 
the second point mutation (G1799D) produced slightly 
different results. As illustrated in Fig. 5 D, the NTPs 
tested showed a similar, relatively small inhibition of 
the current compared with the control solution contain-
ing 210 μM free Mg2+ alone. As in the other mutant, 
  however, there was no signifi  cant difference between 
Mg·ATP, Mg·GTP, and Mg·ITP. The ∆-kinase mutant, 
on the other hand showed a very pronounced block of 
TRPM7 in the presence of nucleotides compared with 
the same free magnesium concentration alone (Fig. 
5 E). However, the block was similar for all three nucle-
otides tested. These results indicate that the inhibitory 
action of the nucleotides is primarily mediated via bind-
ing to the channel’s endogenous kinase domain, which 
does discriminate between nucleotide species. The 
complete removal of the kinase domain reenables 
 nucleotides to inhibit TRPM7, which may be explained 
by exposure of a previously inaccessible binding site 
  extrinsic to TRPM7 kinase domain that does not discri-
minate between nucleotide species.
DISCUSSION
The results of the present study fi  rmly establish that 
both free Mg2+ and Mg-nucleotide complexes (but not 
free nucleotides) regulate the channel activity of 
TRPM7. Either of these factors individually can suppress 
TRPM7 currents, and their combined presence causes a 
mutually synergistic inhibition by shifting the respective 
dose–response curves of either molecule. Normal physi-
ological levels of Mg2+ and Mg-  nucleotides can largely 
account for the reduced basal activity of TRPM7 chan-
nels in resting cells, and reduction in   either one will 
lead to up-regulation of channel activity. We also ob-
served signifi  cant differences in the effi  cacy of various 
species of Mg-nucleotides, with the physiologically most 
relevant adenosine and guanosine   nucleotides being 
TABLE II
Inhibition of TRPM7 by Di- and Triphosphate Nucleotides
Nucleotide IC50 (μM) Nucleotide IC50 (μM)
ATP 128 ± 18 (n = 4–8) ADP 249 ± 81 (5–6)
GTP 342 ± 95 (n = 5–12) GDP 479 ± 96 (n = 5–8)
ITP 758 ± 60 (n = 5–19) IDP 187 ± 73 (n = 5–8)
CTP 278 ± 103 (n = 5–11) CDP 874 ± 309 (n = 5–6)
TTP 175 ± 42 (n = 4–8) TDP 466 ± 89 (n = 6–15)
UTP 375 ± 25 (n = 5–10) UDP 655 ± 76 (n = 6–7)
None 720 ± 79 (n = 6–10)
Comparison of half maximal inhibitory concentrations (IC50) of free Mg2+ 
at fi  xed 6 mM NTP and NDP. The whole-cell currents were recorded in 
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the most potent ones. Both nucleotide tri- and diphos-
phates, but not monophosphates, were effective in regu-
lating TRPM7 channels. The Mg-nucleotide   inhibition 
is likely mediated by a nucleotide binding site on the 
TRPM7 kinase domain, since point mutations that af-
fect phosphotransferase activity of the kinase domain by 
interfering with nucleotide binding suppressed the Mg-
nucleotide–mediated inhibition of channel activity.
Regulation of TRPM7 via Mg2+ and Mg·ATP
The inhibition of TRPM7 by Mg·ATP has been debated 
since the discovery of this protein. Our group proposed 
an inhibition by both free Mg2+ and Mg·ATP (Nadler 
et al., 2001; Schmitz et al., 2003), while a parallel study 
postulated activation by increasing intracellular ATP 
concentrations (Runnels et al., 2001). This issue has 
been resolved and the ATP-mediated activation of 
TRPM7 was ultimately due to a decrease in free Mg2+ 
caused by Na·ATP. The ability of Mg·ATP to suppress 
TRPM7 has been challenged by Kozak and Cahalan 
(2003) based on experiments in which free Mg2+ was 
maintained at low levels and EGTA and HEDTA were 
used to buffer free Mg2+. That study presented two 
  datasets where free Mg2+ was buffered to 270 μM with 
  either 12 mM EGTA or by EGTA (3 mM) + HEDTA 
(2.5 mM) + Mg·ATP (5 mM). Both solutions caused 
a very similar inhibition of TRPM7 by  75%, so the 
  authors concluded that inhibition is via Mg2+ alone and 
that Mg·ATP is ineffective when a strong Mg2+ chelator 
such as HEDTA is used. This conclusion rests entirely 
on the accuracy of these two data points. We there-
fore replicated the exact experimental conditions and 
we fi  nd that the solution containing EGTA (3 mM) + 
HEDTA (2.5 mM) + Mg·ATP (5 mM) indeed produces 
 80% inhibition of the current, which is similar to the 
block Kozak and Cahalan report under those condi-
tions. However, we do not observe a signifi  cant inhibi-
tion of TRPM7 currents by 270 μM free Mg2+ buffered 
with 12 mM EGTA. Since the 12 mM EGTA control 
solution, which Kozak and Cahalan use as a reference 
point, produces a  75% block compared with 0 Mg2+, 
it would correspond to an IC50 of  150 μM for the 
Mg2+-dependent inhibition of TRPM7. In the absence 
of a full dose–response curve that would confi  rm such 
a very low IC50, we point out that our previous studies 
(Nadler et al., 2001; Schmitz et al., 2003), as well as the 
data presented here in Fig. 2 B, consistently place the 
IC50 of Mg2+-dependent TRPM7 block at  700 μM, a 
value that is in excellent agreement with the IC50 of 660 
μM obtained by others (Nadler et al., 2001; Kozak et al., 
2002; Prakriya and Lewis, 2002; Schmitz et al., 2003). Im-
portantly, Mg·ATP can inhibit TRPM7 in the absence of 
any chelator, which provides a compelling argument for 
a key role of this nucleotide in shaping TRPM7 channel 
activity in physiolo  gically more relevant   circumstances. 
Further support for the nucleotide-mediated regulation 
Figure    5.  Phosphotransferase-
defi   cient point mutants of 
TRPM7 affect NTP inhibi-
tion. Whole cell currents were 
recorded in HEK-293 cells in-
duced to overexpress human 
TRPM7 WT or human TRPM7 
mutants. The intracellular 
calcium buffer was Cs-BAPTA. 
(A) HEK-293 cells induced to 
over    express human TRPM7 
WT. Comparison of TRPM7 
current inhibition by 6 mM 
Mg·ATP, Mg·GTP, Mg·ITP, 
and no nucleotide. In all con-
ditions, free Mg2+ concentra-
tion was clamped at 210 μM 
(n = 5–20). (B) Comparison of 
TRPM7 current   inhibition by 
6 mM Mg·ATP and Mg·ITP 
with free Mg2+ concentration 
clamped at 1,600 μM (n = 7–8). 
(C) HEK-293 cells induced to 
overexpress human TRPM7 
point mutation K1648R. Com-
parison of TRPM7 current 
inhibition by 6 mM Mg·ATP, Mg·GTP, Mg·ITP, or no nucleotide. In all conditions, free Mg2+ concentration was clamped at 210 μM (n = 
6–11). (D) HEK-293 cells induced to overexpress human TRPM7 point mutation G1977D. Comparison of TRPM7 current inhibition by 
6 mM Mg·ATP, Mg·GTP, Mg·ITP, or no nucleotide. In all conditions, free Mg2+ concentration was clamped at 210 μM (n = 6–12). (E) 
HEK-293 cells induced to overexpress human TRPM7 Δ-kinase mutation. Comparison of TRPM7 current inhibition by 1 mM Mg·ATP, 
Mg·GTP, Mg·ITP, or no nucleotide. In all conditions, free Mg2+ concentration was clamped at 210 μM (n = 6–17).430 TRPM7 Nucleotide Regulation via its Kinase Domain
of TRPM7 comes from a recent study in human retino-
blastoma cells, where Mg·ATP appears to be more ef-
fective than Mg2+ alone in inhibiting TRPM7 whole-cell 
currents (Hanano et al., 2004).
Nevertheless, the HEDTA experiments offer addi-
tional insight into TRPM7 regulation by free Mg2+. With 
HEDTA and no added Mg2+, we observed in the fi  rst 
100 s both accelerated activation kinetics as well as 
larger peak currents of TRPM7 currents compared with 
BAPTA, which would be consistent with HEDTA’s more 
effective chelation of cytosolic Mg2+. This suggests that 
in the absence of a strong Mg2+ chelator, cells can coun-
teract the decrease in Mg2+ imposed by a Mg2+-free pi-
pette solution, at least temporarily, by mobilizing Mg2+ 
from intracellular stores. By adding HEDTA, this Mg2+ 
would be effectively captured and result in a faster and 
larger increase in TRPM7 current. Interestingly, how-
ever, the current subsequently decays to levels compara-
ble to or even below those seen at steady state with 
BAPTA. Since addition of just 200 μM free Mg2+ pre-
vents this HEDTA-mediated decay without signifi  cantly 
reducing the peak current magnitude, it is conceivable 
that some Mg2+ may be required for proper channel 
function, while higher levels of Mg2+ inhibit TRPM7. 
Alternatively, this effect may be due to a pharmacologi-
cal effect of the buffers where either HEDTA enhances 
and/or BAPTA inhibits TRPM7 directly. Another possi-
bility could be related to the fact that TRPM7 has a Zn2+ 
binding site. Since HEDTA is a very effi  cient buffer 
for this ion, the removal of Zn2+ might compromise 
TRPM7’s molecular structure.
Our results demonstrate that free Mg2+ alone, in the 
absence of added Mg·ATP, is capable of suppressing 
TRPM7 currents, whereas free ATP alone is without 
  effect. In fact, free ATP will effectively chelate any free 
Mg2+ and thereby cause activation of TRPM7 via a de-
crease in free Mg2+. We established the effi  cacy of free 
Mg2+ in the absence of any added ATP and arrived at an 
IC50 of 720 μM. Due to its Mg2+ binding, it is impossible 
to test the effects of Mg·ATP in isolation, since the com-
plexed nucleotide will be in equilibrium with free Mg2+ 
according to its dissociation constant. We determined 
the effi  cacy of Mg·ATP at the lowest possible levels of 
free Mg2+ (  200 μM) to be 3.3 mM. When putting 
these values into a physiological context, where free 
Mg2+ is thought to be in the range of 0.5–1 mM and 
Mg·ATP in the range of 3–4 mM in most cells, it is 
  obvious that neither free Mg2+ alone nor Mg·ATP alone 
can account for the constitutive suppression of TRPM7 
  currents. We estimate that TRPM7 activity in a resting 
cell is suppressed by  93% based on the ratio of peak 
currents in the absence of Mg2+ and Mg·ATP (150 pA/
pF, n = 9, 10 mM BAPTA; see Fig. 2 A) and the basal 
current obtained immediately following break-in (14 
pA/pF, n = 48). When perfused with highly inhibitory 
solutions (high Mg2+ and/or high Mg·ATP), this basal 
current fi  rst decreases, but in time TRPM7 currents in-
crease again and reach higher values. Thus, assuming 
physiological levels of Mg2+ (0.8 mM) and Mg·ATP 
(4 mM), their individual contributions would account 
for 34% and 51% inhibition, respectively (see Fig. 2, B 
and D, for the dose responses), and the combination of 
both factors would yield 85%. We therefore   assume that 
the combined effects of the two regulators may account 
for most of the suppression experienced by TRPM7 un-
der resting conditions, but there may well be additional 
  factors (e.g., GTP and GDP, spermine, etc.) that further 
reduce TRPM7 activity to arrive at 93%.
Synergy between Mg2+ and Mg·ATP
Mg·ATP is the essential nucleotide complex that binds 
to the active site of all known protein kinases and the 
presence of both Mg2+ and ATP is necessary to support 
phosphorylation (Adams, 2001). The TRPM7 kinase 
domain is atypical, but the analysis of its crystal struc-
ture revealed a striking resemblance to classical protein 
kinases (Yamaguchi et al., 2001). The present investiga-
tion offers some insight into the interactions between 
free Mg2+ and Mg·ATP in regulating TRPM7 activity. 
We established dose–response curves of TRPM7 current 
inhibition by increasing the Mg·ATP concentration at 
fi   xed low ( 200  μM), physiological ( 800  μM), or 
high ( 1600 μM) free Mg2+ concentrations. There was 
only a modest shift in the IC50 for Mg·ATP-mediated in-
hibition of TRPM7 from 3.3 ± 0.5 mM (at 200 μM free 
Mg2+) to 2.0 ± 0.8 mM at 800 μM free Mg2+ and no sig-
nifi  cant further sensitization at 1.6 mM free Mg2+. While 
this amounts to a twofold shift in the IC50 for Mg·ATP, it 
is important to note that this shift occurs at relatively 
low concentrations of free Mg2+ and is essentially com-
plete at 800 μM free Mg2+. This suggests that slight vari-
ations in free Mg2+ around physiological levels may not 
have a major impact on the nucleotide sensitivity of 
TRPM7. Conversely, the effi  cacy of free Mg2+ is shifted 
about one order of magnitude when increasing Mg·ATP 
from 0 to 6 mM. Even for physiologically relevant Mg·ATP 
concentrations between 1 and 4 mM, the shift in IC50 
for Mg2+ was fourfold. Therefore, it appears that free 
Mg2+ and Mg·ATP are acting in synergy (or coopera-
tively) to inhibit TRPM7, since they differentially affect 
each other’s inhibitory effi  cacy.
Mono-, Di-, and Triphosphate Nucleotide Effects
When testing for different adenosine phosphates, we 
were surprised that Mg·ADP inhibited TRPM7 currents 
with a very similar effi  cacy as the triphosphate nucleo-
tide. Both Mg·ATP and Mg·ADP at 6 mM were able to 
enhance the inhibition of TRPM7 current by free Mg2+ 
(5.6- and 3-fold, respectively). However, equivalent AMP 
concentrations in the presence of physiological levels of 
free Mg2+ showed no effect on TRPM7 current. Since 
AMP does not complex Mg2+, this result suggests that   Demeuse et al.  431
only the full Mg-nucleotide complex can act as an in-
hibitor of TRPM7.
These results also indicate that a simple decrease in 
Mg·ATP levels would not be suffi  cient to cause a massive 
activation of TRPM7 as long as the total amount of     
di- and triphosphate species remains constant. One of the 
conserved features between TRPM7 kinase and classical 
protein kinases is a strictly conserved lysine residue (Lys-
72 in PKA, Lys-1648 in human TRPM7), which interacts 
with the α- and β-phosphates of ATP (Yamaguchi et al., 
2001). It is therefore conceivable that this lysine residue 
could also interact and stabilize ADP binding for a similar 
inhibitory effect. As a consequence of this dual regulation, 
ADP may serve as a safeguard that prevents excessive 
TRPM7 activation when ATP   levels fl  uctuate under nor-
mal physiologic conditions. This safeguard system may fail 
in pathophysiological   situations, such as hypoxia or hypo-
glycemia, and may contribute to cellular calcium overload 
and cell death (Nadler et al., 2001; Aarts et al., 2003).
While ATP and ADP were the most potent of all the 
  nucleotides tested to block TRPM7 channels, nearly all 
other Mg·NTP and Mg·NDP tested were also effective to 
varying degrees (see Fig. 4). Although the physiological 
concentration of Mg·ATP can reach up to 6 mM, the 
physiological concentrations of the purine and  pyrimidine 
nucleotides are of course lower. The average values for 
total intracellular nucleotide triphosphates in mamma-
lian cells (Traut, 1994) were found to be 3.152 ± 1.698 
mM, 468 ± 224 μM, 567 ± 460 μM, and 278 ± 242 μM 
for ATP, GTP, UTP, and CTP, respectively. The free Mg2+ 
concentration was estimated at 1.1 mM and complexed 
Mg at 8 mM. The initial potentiation of TRPM7 that is 
followed by inactivation with   increasing GTP concentra-
tions is likely due to the G protein regulation of TRPM7 
(Takezawa et al., 2004). The rather low potency of ITP 
block compared with ATP is striking, although a previous 
study made a similar observation on rat heart KATP chan-
nels, where ATP, ADP, and CTP strongly inhibited the 
channels but ITP was much less effective (Lederer and 
Nichols, 1989). The molecules are very similar (the OH 
group of adenosine is replaced by NH2 at the 6’ position 
in inosine), and it is quite surprising that they exhibit 
vastly different behavior in suppressing TRPM7 currents, 
whereas structurally more distinct nucleotides like CTP 
and TTP were relatively potent inhibitors. ATP and ITP 
also complex Mg2+ with similar potency, making a differ-
ence at that level unlikely. There may be nucleotide-spe-
cifi  c conformational changes in TRPM7 molecule that 
infl  uence the closing of the channel, possibly due to dif-
ferences in hydrogen bonding that stabilize the nucleo-
tide at the binding site.
The Kinase Domain Mediates the Nucleotide-dependent 
Regulation of Channel Function
Nucleotides are known to affect the phosphotransferase 
activity of protein kinases, but an important unresolved 
question pertaining to the TRPM7 ion channel is 
whether the kinase component can regulate the channel 
(or vice versa). One model of TRPM7 function proposed 
that the kinase domain is essential for gating the chan-
nel (Runnels et al., 2001). In contrast, we previously 
demonstrated that mutant TRPM7 channels without 
phosphotransferase activity still exhibit channel activa-
tion comparable to wt TRPM7 and are still regulated by 
Mg2+ and Mg·ATP (Schmitz et al., 2003). We also found 
that the cAMP/PKA signaling pathway can regulate 
TRPM7 activity through the channel’s kinase domain, 
as phosphotransferase-defi  cient mutants are no longer 
regulated by that pathway (Takezawa et al., 2004). A re-
cent study argues for a complete dissociation of TRPM7 
channel function and regulation by Mg2+ or autophos-
phorylation by kinase activity (Matsushita et al., 2005). 
Our results in the present study show the loss of Mg·ATP 
and Mg·GTP block in the phosphotransferase-defi  cient 
mutant K1648R. The lysine residue mutated is impli-
cated in catalysis and is conserved in classical kinases 
(Yamaguchi et al., 2001; Matsushita et al., 2005). In the 
second mutant G1799D, some regulation remains, even 
though phosphotransferase activity is lost. This second 
mutation may be involved in peptide substrate binding 
or orientation of the substrate-binding loop (Yamaguchi 
et al., 2001; Matsushita et al., 2005).
An important question relates to whether the nucleo-
tide binding alone is suffi  cient to regulate TRPM7 chan-
nel activity or whether kinase activity per se also plays a 
role, since this domain can autophosphorylate the 
  channel. The primary residue of this phosphorylation is 
a matter of controversy, since some groups observe phos-
phorylation of serine (Ryazanova et al., 2004;   Matsushita 
et al., 2005), while another identifi  ed threonine as a tar-
get (Hermosura et al., 2005). TRPM7 has also been 
identifi   ed to phosphorylate other proteins such as 
  annexin (Dorovkov and Ryazanov, 2004). Ryazanova 
et al. (2004) found that the TRPM7 kinase domain can-
not use Mg·GTP as a phosphate donor for phosphoryla-
tion reactions. It was speculated that one of the GTP 
oxygens would repel E1718 in the nucleotide binding 
site. Our data here argue that Mg·GTP might in fact be 
able to bind to the nucleotide-binding site, as this nucle-
otide clearly is effi  cient in suppressing current activity. 
This observation and our kinase mutant data support 
the notion that the inhibitory effects seen by Mg·NTPs 
are largely independent of the channel’s kinase activity 
and that Mg-nucleotide binding itself is suffi  cient.
At variance with other reports, Hermosura et al. 
(2005) recently identifi  ed threonin-1428 as a signifi  cant 
locus for TRPM7 autophosphorylation. This study also 
reported that disabling this phosphorylation site by a 
T1428I point mutation not only reduced the phosphate 
incorporation by 30% but also changed the sensitivity 
of the channel toward inhibition by free Mg2+. The 
  authors found that 1 mM added free Mg2+ reduced the 432 TRPM7 Nucleotide Regulation via its Kinase Domain
currents of the T1428I mutant by  50% compared with 
Mg2+-free solutions. This value on its own would not 
suggest an overly sensitive channel, since it is in fact 
very similar to the degree of Mg2+-induced inhibition 
  observed in numerous studies on heterologous (Nadler 
et al., 2001; Schmitz et al., 2003) or native TRPM7 
(Kozak et al., 2002; Prakriya and Lewis, 2002), including 
the IC50 observed in the present study (see Fig. 1 and 2). 
However, in the context of that study, the same concen-
tration of Mg2+ produced a surprisingly small inhibition 
of wt TRPM7 of <20%. Our attempts to reproduce 
those data under the same experimental conditions in 
the same HEK-293 cells overexpressing wt TRPM7 were 
not successful (see Fig. 3 D), and we therefore cannot 
conclude that the phosphorylation state of that particu-
lar threonine residue is important for shaping Mg2+ 
and/or Mg-nucleotide sensitivity. It should be noted 
that a sensitization would be rather unexpected and in 
apparent confl  ict with the reduced Mg2+ and Mg·ATP 
sensitivity reported for phosphotransferase-defi  cient 
mutants, which would likely also result in a dephos-
phorylated protein.
Multiple Binding Sites for Mg2+ and Mg·ATP Inhibition
Magnesium is the only intracellular divalent cation, 
present in vivo at concentrations >1 μM, that has a 
strong affi  nity for polyphosphate ions (da Silva and 
  Williams, 2001). Therefore, NTP4− are complexed nearly 
exclusively to Mg2+ in cells, and protein kinases use 
the Mg2+ complex of ATP as a substrate rather than 
free ATP4− anion. In most protein kinases, the appar-
ent Km for Mg·ATP decreases with increasing concen-
trations of free Mg2+. Given the predicted similarity in 
magnesium coordination between different Ser/Thr 
protein kinases and the striking resemblance of struc-
ture (but not of sequence) between the TRPM7 kinase 
domain and typical protein kinases (Sigel et al., 2001; 
Kim et al., 2005), it is tempting to suggest that TRPM7 
also possesses a magnesium binding site. Especially 
since mutant TRPM7 proteins whose nucleotide bind-
ing site has been mutated retain Mg2+ sensitivity, and 
truncation mutants without the entire kinase domain 
are even more sensitive to Mg2+ inhibition (Schmitz 
et al., 2003). Fig. 6 represents the simplest hypothetical 
model describing the Mg2+ and Mg-nucleotide regula-
tion of TRPM7. [ID]FIG6[ID]
As illustrated in the model, the wt TRPM7 channel 
may possess two distinct binding sites for Mg2+ and 
Mg·NTP, the latter being located within the channel’s 
  endogenous kinase domain and the former upstream, 
possibly close to inner mouth of the channel. Our data sug-
gest that both sites cooperatively mediate the synergistic 
  inhibition of TRPM7 by free Mg2+ and Mg-nucleotides. 
The sensitivity of the channel toward these inhibitors is 
relatively high, resulting in >90% inhibition at physio-
logical levels of free Mg2+ and Mg·NTP. The modifi-
cation of TRPM7 by point mutations that prevent 
signifi  cant nucleotide binding or coordination to the 
kinase domain essentially removes the nucleotide-
  mediated component and only leaves the Mg2+-
  dependent regulatory site. This effectively disrupts the 
synergy between the two sites and renders the channel 
largely insensitive to nucleotide regulation at low levels 
of Mg2+ and also lowers the sensitivity to block by free 
Mg2+ itself. We cannot rule out that the point mutants re-
tain some small capacity of nucleotide binding that could 
become more obvious at higher levels of free Mg2+. This 
could explain why these point mutants can be inhibited 
by very high concentrations of Mg·ATP in the presence of 
500 μM free Mg2+ (Schmitz et al., 2003). Finally, when 
removing the kinase domain entirely, we see the opposite 
effect, in that kinase deletion mutants are more sensitive 
to both free Mg2+ and Mg-nucleotides. We hypothesize 
that the truncation of the COOH-terminal kinase  domain 
exposes the Mg2+ binding site and converts it into a high-
affi  nity site that can be blocked by very low levels of free 
Mg2+. In addition, this site now becomes available for 
binding Mg-nucleotides. However, since the kinase dele-
tion mutant does not discriminate between nucleotide 
species, we assume that it simply accepts the Mg- phosphate 
moiety as a binding partner. This model considers Mg2+ 
and Mg-nucleotide binding as primary regulators of 
channel activity, although the phosphorylation status of 
the channel may contribute to its sensitivity toward these 
inhibitors (Schmitz et al., 2003).
Conclusions
The present study resolves two controversial issues 
  regarding the relative roles of Mg-nucleotides and the 
endogenous kinase domain in regulating TRPM7 chan-
nel activity. While in contrast to a confl  icting report by 
Cahalan and colleagues that disputes the ability of Mg-
nucleotides to regulate TRPM7 (Kozak and Cahalan, 
2003), the comprehensive analysis presented here pro-
vides unambiguous evidence that Mg·nucleotides do in 
fact regulate TRPM7 channels by inhibiting channel ac-
tivity in synergy with free Mg2+. This extends and cor-
roborates the original observation of the Mg-nucleotide 
regulation (Nadler et al., 2001) and reaffi  rms the apt-
ness of the originally proposed term MagNuM (for 
magnesium-nucleotide regulated metal ion current) 
put forward in the fi  rst two published accounts of heter-
ologous and native TRPM7 currents (Nadler et al., 2001; 
Hermosura et al., 2002). The nucleotide-dependent reg-
ulation of TRPM7 appears to be mediated by a binding 
site within the endogenous kinase domain and therefore 
reaffi  rms that the kinase domain is linked to channel 
function and not completely separate as proposed by 
  Cahalan and colleagues (Matsushita et al., 2005). This regu-
lation is seen with nearly all NTPs and NDPs, and nucleo-
tide specifi  city is imparted by the nucleotide binding 
site as demonstrated by phosphotransferase-defi  cient   Demeuse et al.  433
point mutants. These data complement our previous dem-
onstration of the kinase domain’s parti  cipation in the re-
ceptor-mediated regulation of TRPM7 via cAMP and 
PKA (Takezawa et al., 2004).
We thank Carolyn E. Oki and Ka’ohimanu L. Dang for expert 
technical assistance and Carsten Schmitz (University of Denver, 
Denver, CO) for providing the mutant TRPM7 TrexHEK293 
cell lines.
This work was supported by National Institutes of Health grant 
R01-GM065360 to A. Fleig, and R01-NS040927 to R. Penner.
Olaf S. Andersen served as editor.
Submitted: 21 September 2005
Accepted: 15 February 2006
R  E  F  E  R  E  N  C  E  S 
Aarts, M., K. Iihara, W.L. Wei, Z.G. Xiong, M. Arundine, W. 
Cerwinski, J.F. MacDonald, and M. Tymianski. 2003. A key role for 
TRPM7 channels in anoxic neuronal death. Cell. 115:863–877.
Adams, J.A. 2001. Kinetic and catalytic mechanisms of protein 
  kinases. Chem. Rev. 101:2271–2290.
da Silva, J.J.R.F., and R.J.P. Williams. 2001. The Biological Chemistry 
of the Elements: the Inorganic Chemistry of Life. Second edition. 
Oxford University Press, Oxford. 575 pp.
Dorovkov, M.V., and A.G. Ryazanov. 2004. Phosphorylation of annexin 
I by TRPM7 channel-kinase. J. Biol. Chem. 279:50643–50646.
Fleig, A., and R. Penner. 2004. The TRPM ion channel subfamily: 
molecular, biophysical and functional features. Trends Pharmacol. 
Sci. 25:633–639.
Gwanyanya, A., B. Amuzescu, S.I. Zakharov, R. Macianskiene, 
K.R. Sipido, V.M. Bolotina, J. Vereecke, and K. Mubagwa. 2004. 
Magnesium-inhibited, TRPM6/7-like channel in cardiac myocytes: 
permeation of divalent cations and pH-mediated regulation. 
J. Physiol. 559:761–776.
Hanano, T., Y. Hara, J. Shi, H. Morita, C. Umebayashi, E. Mori, 
H. Sumimoto, Y. Ito, Y. Mori, and R. Inoue. 2004. Involvement 
of TRPM7 in cell growth as a spontaneously activated Ca2+ en-
try pathway in human retinoblastoma cells. J. Pharmacol. Sci. 
95:403–419.
Harteneck, C. 2005. Function and pharmacology of TRPM cation 
channels. Naunyn Schmiedebergs Arch. Pharmacol. 371:307–314.
Hermosura, M.C., M.K. Monteilh-Zoller, A.M. Scharenberg, R. 
Penner, and A. Fleig. 2002. Dissociation of the store-operated 
  calcium current I(CRAC) and the Mg-nucleotide-regulated metal 
ion current MagNuM. J. Physiol. 539:445–458.
Hermosura, M.C., H. Nayakanti, M.V. Dorovkov, F.R. Calderon, A.G. 
Ryazanov, D.S. Haymer, and R.M. Garruto. 2005. A TRPM7 vari-
ant shows altered sensitivity to magnesium that may contribute to 
the pathogenesis of two Guamanian neurodegenerative disorders. 
Proc. Natl. Acad. Sci. USA. 102:11510–11515.
Jiang, J., M. Li, and L. Yue. 2005. Potentiation of TRPM7 inward 
currents by protons. J. Gen. Physiol. 126:137–150.
Kim, C., N.H. Xuong, and S.S. Taylor. 2005. Crystal structure of a 
complex between the catalytic and regulatory (RIα) subunits of 
PKA. Science. 307:690–696.
Kozak, J.A., and M.D. Cahalan. 2003. MIC channels are inhibited by 
internal divalent cations but not ATP. Biophys. J. 84:922–927.
Kozak, J.A., H.H. Kerschbaum, and M.D. Cahalan. 2002. Distinct 
properties of CRAC and MIC channels in RBL cells. J. Gen. Physiol. 
120:221–235.
Kozak, J.A., M. Matsushita, A.C. Nairn, and M.D. Cahalan. 2005. 
Charge screening by internal pH and polyvalent cations as a 
mechanism for activation, inhibition, and rundown of TRPM7/
MIC channels. J. Gen. Physiol. 126:499–514.
Lederer, W.J., and C.G. Nichols. 1989. Nucleotide modulation of 
the activity of rat heart ATP-sensitive K+ channels in isolated 
membrane patches. J. Physiol. 419:193–211.
Matsushita, M., J.A. Kozak, Y. Shimizu, D.T. McLachlin, H. 
Yamaguchi, F.Y. Wei, K. Tomizawa, H. Matsui, B.T. Chait, M.D. 
Cahalan, and A.C. Nairn. 2005. Channel function is dissociated 
from the intrinsic kinase activity and autophosphorylation of 
TRPM7/ChaK1. J. Biol. Chem. 280:20793–20803.
Monteilh-Zoller, M.K., M.C. Hermosura, M.J. Nadler, A.M. 
Scharenberg, R. Penner, and A. Fleig. 2003. TRPM7 provides an 
ion channel mechanism for cellular entry of trace metal ions. 
J. Gen. Physiol. 121:49–60.
Nadler, M.J., M.C. Hermosura, K. Inabe, A.L. Perraud, Q. Zhu, A.J. 
Stokes, T. Kurosaki, J.P. Kinet, R. Penner, A.M. Scharenberg, and 
A. Fleig. 2001. LTRPC7 is a Mg.ATP-regulated divalent cation 
channel required for cell viability. Nature. 411:590–595.
Prakriya, M., and R.S. Lewis. 2002. Separation and characterization 
of currents through store-operated CRAC channels and Mg2+-
  inhibited cation (MIC) channels. J. Gen. Physiol. 119:487–507.
Pusch, M., and E. Neher. 1988. Rates of diffusional exchange be-
tween small cells and a measuring patch pipette. Pfl  ugers Arch. 
411:204–211.
Runnels, L.W., L. Yue, and D.E. Clapham. 2001. TRP-PLIK, a bi-
functional protein with kinase and ion channel activities. Science. 
291:1043–1047.
Runnels, L.W., L. Yue, and D.E. Clapham. 2002. The TRPM7 chan-
nel is inactivated by PIP(2) hydrolysis. Nat. Cell Biol. 4:329–336.
Ryazanova, L.V., M.V. Dorovkov, A. Ansari, and A.G. Ryazanov. 2004. 
Characterization of the protein kinase activity of TRPM7/ChaK1, 
a protein kinase fused to the transient receptor potential ion 
channel. J. Biol. Chem. 279:3708–3716.
Ryazanova, L.V., K.S. Pavur, A.N. Petrov, M.V. Dorovkov, and 
A.G. Ryazanov. 2001. Novel type of signaling molecules: pro-
tein kinases covalently linked with ion channels. Mol. Biol. 
35:271–283.
Figure 6.  Hypothetical model of Mg2+ and Mg-nucleotide regu-
lation of TRPM7. The model depicts the binding of Mg2+ and 
Mg·NTP to the wt TRPM7 channel, the phosphotransferase-
  defi   cient point mutant K1648R, and the ∆-kinase truncation 
  mutant. The wt TRPM7 channel provides two distinct sites (M and 
N sites) that jointly confer intermediate sensitivity to Mg2+ and 
Mg·NTP. The functional kinase domain (highlighted in orange) 
harbors the N site and awards specifi  city for various nucleotide 
species. The phosphotransferase-defi  cient mutant lacks the func-
tional N site and is primarily regulated by the M site, but the loss 
of the synergistic N site interaction results in a channel with re-
duced susceptibility to Mg2+ block. Finally, the ∆-kinase trunca-
tion mutant completely eliminates the kinase domain and the 
N site, but exposes the M site, which previously was only accessible 
to Mg2+, to NTP binding. This results in a channel with enhanced 
sensitivity to both Mg2+ and NTP, but does not impart nucleotide 
specifi  city, suggesting that the Mg·NTP may simply function as a 
Mg donor to the M site.434 TRPM7 Nucleotide Regulation via its Kinase Domain
Schmitz, C., A.L. Perraud, C.O. Johnson, K. Inabe, M.K. Smith, 
R. Penner, T. Kurosaki, A. Fleig, and A.M. Scharenberg. 2003. 
Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. 
Cell. 114:191–200.
Sigel, H., E.M. Bianchi, N.A. Corfu, Y. Kinjo, R. Tribolet, and R.B. 
Martin. 2001. Stabilities and isomeric equilibria in solutions of mo-
nomeric metal-ion complexes of guanosine 5′-triphosphate (GTP4-) 
and inosine 5′-triphosphate (ITP4-) in comparison with those of 
adenosine 5′-triphosphate (ATP4-). Chemistry. 7:3729–3737.
Takezawa, R., C. Schmitz, P. Demeuse, A.M. Scharenberg, R. Penner, 
and A. Fleig. 2004. Receptor-mediated regulation of the TRPM7 
channel through its endogenous protein kinase domain. Proc. 
Natl. Acad. Sci. USA. 101:6009–6014.
Traut, T.W. 1994. Physiological concentrations of purines and 
  pyrimidines. Mol. Cell. Biochem. 140:1–22.
Yamaguchi, H., M. Matsushita, A.C. Nairn, and J. Kuriyan. 2001. 
Crystal structure of the atypical protein kinase domain of a TRP 
channel with phosphotransferase activity. Mol. Cell. 7:1047–1057.